Cash, cash equivalents and marketable securities totaled $16.9M as of March 31 compared with $23.2M as of December 31, 2024. Unity believes that current cash, cash equivalents and marketable securities are sufficient to fund operations into the fourth quarter of 2025. “The 24-week data indicates that UBX1325, acting via a novel mechanism of action, can lead to vision improvement in patients with inadequate response to standard of care,” said Anirvan Ghosh, chief executive officer of Unity. “The full 36-week data will be instrumental in shaping our plans for subsequent studies.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UBX:
- Unity Biotechnology price target lowered to $4 from $8 at H.C. Wainwright
- Unity Biotechnology price target lowered to $4 from $6 at Chardan
- Positive Outlook for Unity Biotechnology Despite Initial Setback in UBX1325 Study
- Unity Biotechnology announces results from ASPIRE Phase 2b study in DME
- Unity Biotechnology Appoints Dr. Yehia Hashad to Board